Biogen announced that the U.S. Food and Drug Administration, FDA, has accepted for review the abbreviated Biologics License Application, aBLA, for BIIB800, a biosimilar candidate referencing ACTEMRA, an anti-interleukin-6 receptor monoclonal antibody. "The FDA filing is supported by Phase 3 data from a comparative clinical trial demonstrating equivalent efficacy and a comparable safety and immunogenicity profile to the reference product," said Ian Henshaw, Head of Global Biosimilars at Biogen. "We look forward to working with regulators to bring this potential treatment option for people with immune mediated inflammatory diseases." In September 2022, the Marketing Authorization Application for BIIB800 was accepted for review by the European Medicines Agency.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BIIB:
- FDA Accepts Biogen Biologics License Application for BIIB800, A Biosimilar Candidate Referencing ACTEMRA® (tocilizumab)
- European Patent Offices’ EBA denies Forward’s EP2801355 petition for review
- Biogen and Sage Therapeutics to hold a joint investor webcast
- Sage Therapeutics, Biogen complete NDA to FDA for zuranolone
- European Medicines Agency Accepts Tofersen Marketing Authorization Application to Treat Rare, Genetic Form of ALS